WTX-330 Clin1 oncology; WTX-613 Clin0 oncology; WTX-712 RD tumors; Indukine molecules RD immuno-oncology, autoimmune and inflammatory disease
Werewolf Therapeutics is pioneering conditionally activated macrophage therapies for the treatment of cancer. Their work revolves around PREDATOR, a proprietary platform that designs and engineers macrophages to specifically target and destroy cancer cells. PREDATOR macrophages are activated selectively within the tumor microenvironment, minimizing off-target effects and maximizing therapeutic impact. Werewolf Therapeutics' lead product candidates, WTX-124 and WTX-330, are conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. These therapies leverage the inherent tumor-fighting abilities of macrophages to effectively target and eliminate cancer cells while minimizing systemic toxicity.